Shipped at 4°C. Store at -20°C. Store under desiccating conditions.Product descriptionNavitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL,
Shipped at 4°C. Store at -20°C. Store under desiccating conditions.Product descriptionNavitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL,
Shipped at 4°C. Store at -20°C. Store under desiccating conditions.Product descriptionNavitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL,
Shipped at 4°C. Store at -20°C. Store under desiccating conditions.Product descriptionNavitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL,
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.
AVL-292 is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <:0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.